Key facts
- It has raised $1.1M; the latest was Later Stage VC ($3.5M) in Dec 2025.
- Notable investors include US National Science Foundation, United States Department of War, Keiretsu Forum, Ohio Department of Development, Case Western Reserve University — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Haima Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Haima Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Haima Therapeutics
Operator of a biotechnology company intended to develop cell-inspired therapies to mitigate bleeding and other blood-related disorders. The company's novel fully-synthetic nanoparticle-based hemostatic technology mitigates bleeding by acting at the site of injury and amplifying the body's natural clotting mechanisms, enabling patients to recover fast from traumatic injury, surgery, and a variety of blood-related ailments.
- Sector
- Healthcare
- HQ
- Cleveland, OH, United States
- Founded
- 2016
- Employees
- 6
- Website
- haimatherapeutics.com/
- Ownership
- Privately Held (backing)
Haima Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Haima Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Haima Therapeutics in its N-PORT filings yet. We sweep new filings monthly.